Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
TAK-715
CHF 0.00
In stock
SYN-1087-M0011 mgCHF 99.00
SYN-1087-M0055 mgCHF 156.00
SYN-1087-M01010 mgCHF 199.00
SYN-1087-M05050 mgCHF 653.00
SYN-1087-M100100 mgINQ
Product Details | |
---|---|
Synonyms | TAK715 |
Product Type | Chemical |
Properties | |
Formula | C24H21N3OS |
MW | 399.5 |
CAS | 303162-79-0 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO or ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: p38 | Kinase Group: CMGC | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | HEKAIDKUDLCBRU-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Description
TAK-715 is a potent specific inhibitor of the p38α MAP kinase with an IC(50) of 7.1nM. It is approximately 30-fold more selective for p38α over p38β. It shows no inhibition of p38γ/δ.
Product References
- Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent: S. Miwatashi, et al.; J. Med. Chem. 48, 5966 (2005)